Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Hypermutation In Pancreatic Cancer

(2017) Jeremy L. Humphris et al.   GASTROENTEROLOGY

Targeting both tumour-associated CXCR2+neutrophils and CCR2+macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

(2017) Timothy M Nywening et al.   GUT

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

(2017) Vinod P. Balachandran et al.   NATURE

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

(2017) Marta Łuksza et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Identification of essential genes for cancer immunotherapy

(2017) Shashank J. Patel et al.   NATURE

The problem with neoantigen prediction

(2017)   NATURE BIOTECHNOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer

(2017) Julienne L. Carstens et al.   Nature Communications

Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis

(2017) Takahiro Tsujikawa et al.   Cell Reports

Microsatellite Instability

(2017) Liisa Chang et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer

(2017) Tao Shen et al.   Scientific Reports

TGF  Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis

(2016) D. R. Principe et al.   CANCER RESEARCH

γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

(2016) Donnele Daley et al.   CELL

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

(2016) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Microsatellite Instability as a Biomarker for PD-1 Blockade

(2016) J. C. Dudley et al.   CLINICAL CANCER RESEARCH

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

(2016) Thomas A Mace et al.   GUT

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer

(2016) Yaqing Zhang et al.   GUT

Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.

(2016) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

(2016) Timothy M Nywening et al.   LANCET ONCOLOGY

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma

(2016) Anne M Noonan et al.   MOLECULAR THERAPY

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

(2016) Hong Jiang et al.   NATURE MEDICINE

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer

(2016) S Chouaib et al.   ONCOGENE

Targeting tumor tolerance: A new hope for pancreatic cancer therapy?

(2016) Daniel Delitto et al.   PHARMACOLOGY & THERAPEUTICS

The "cancer immunogram"

(2016) C. U. Blank et al.   SCIENCE

Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis

(2016) Bodo E. Lippitz et al.   OncoImmunology

Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma

(2016) Isabel Poschke et al.   OncoImmunology

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma

(2016) Peter Bailey et al.   Scientific Reports

Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer

(2015) N Hiraoka et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma

(2015) Ingunn M. Stromnes et al.   CANCER CELL

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation--An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302

(2015) J. K. Saggar et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

(2015) F. J. Kohlhapp et al.   CLINICAL CANCER RESEARCH

Cancer Neoantigens and Applications for Immunotherapy

(2015) A. Desrichard et al.   CLINICAL CANCER RESEARCH

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages

(2015) Gregory L. Beatty et al.   GASTROENTEROLOGY

Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy

(2015) Giuseppe Di Caro et al.   GUT

Stromal biology and therapy in pancreatic cancer: a changing paradigm

(2015) Albrecht Neesse et al.   GUT

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

(2015) Daniel V.T. Catenacci et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

(2015) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors

(2015) Kevin C. Soares et al.   JOURNAL OF IMMUNOTHERAPY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Whole genomes redefine the mutational landscape of pancreatic cancer

(2015) Nicola Waddell et al.   NATURE

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

(2015) Richard A Moffitt et al.   NATURE GENETICS

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

State of the art and future directions of pancreatic ductal adenocarcinoma therapy

(2015) Cindy Neuzillet et al.   PHARMACOLOGY & THERAPEUTICS

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

(2015) A. Morello et al.   Cancer Discovery

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

(2015) Q. J. Wang et al.   Cancer Immunology Research

Pancreatic Adenocarcinoma

(2015) David P. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas

(2015) Cindy Neuzillet et al.   Oncotarget

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

(2014) Berna C. Özdemir et al.   CANCER CELL

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

(2014) Andrew D. Rhim et al.   CANCER CELL

Adverse Immunoregulatory Effects of 5FU and CPT11 Chemotherapy on Myeloid-Derived Suppressor Cells and Colorectal Cancer Outcomes

(2014) J. Kanterman et al.   CANCER RESEARCH

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions

(2014) Y.-C. Lu et al.   CLINICAL CANCER RESEARCH

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

(2014) S. D. Brown et al.   GENOME RESEARCH

HIF Transcription Factors, Inflammation, and Immunity

(2014) Asis Palazon et al.   IMMUNITY

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

(2014) Gary Middleton et al.   LANCET ONCOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

(2014) Laura Bonapace et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

(2014) E. R. Lutz et al.   Cancer Immunology Research

The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration

(2014) Jennifer Watt et al.   OncoImmunology

Immunological off-target effects of standard treatments in gastrointestinal cancers

(2013) A. G. Duffy et al.   ANNALS OF ONCOLOGY

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

(2013) L Bracci et al.   CELL DEATH AND DIFFERENTIATION

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

(2013) Dung T. Le et al.   JOURNAL OF IMMUNOTHERAPY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the Ras–ERK pathway in pancreatic adenocarcinoma

(2012) Cindy Neuzillet et al.   CANCER AND METASTASIS REVIEWS

Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response

(2012) K. Franciszkiewicz et al.   CANCER RESEARCH

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-  Inducible Chemokines

(2012) W. Peng et al.   CANCER RESEARCH

CD103 or LFA-1 Engagement at the Immune Synapse between Cytotoxic T Cells and Tumor Cells Promotes Maturation and Regulates T-cell Effector Functions

(2012) K. Franciszkiewicz et al.   CANCER RESEARCH

Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study

(2012) Jeffrey M. Hardacre et al.   JOURNAL OF GASTROINTESTINAL SURGERY

The role of stroma in pancreatic cancer: diagnostic and therapeutic implications

(2012) Mert Erkan et al.   Nature Reviews Gastroenterology & Hepatology

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma

(2012) Luigi Laghi et al.   PLoS One

A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma

(2011) Lutz Eric et al.   ANNALS OF SURGERY

A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

(2011) D. T. Le et al.   CLINICAL CANCER RESEARCH

Armed response: how dying cells influence T-cell functions

(2011) Thomas A. Ferguson et al.   IMMUNOLOGICAL REVIEWS

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

(2011) Eric A Collisson et al.   NATURE MEDICINE

Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine

(2010) Ghassan K. Abou-Alfa et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Somatic Mutation Profiles of MSI and MSS Colorectal Cancer Identified by Whole Exome Next Generation Sequencing and Bioinformatics Analysis

(2010) Bernd Timmermann et al.   PLoS One

Epitope Landscape in Breast and Colorectal Cancer

(2008) N. H. Segal et al.   CANCER RESEARCH

Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

(2008) D. Laheru et al.   CLINICAL CANCER RESEARCH